|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's range||29.61 - 31.01|
|52-week range||29.61 - 31.01|
|Beta (5Y monthly)||1.83|
|PE ratio (TTM)||N/A|
|Earnings date||03 Nov 2021 - 08 Nov 2021|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
All of these stocks are more than 40% below their peaks, but at least one important investor thinks they can recover.
Invitae (NYSE: NVTA) shares dropped 17% in July as investors moved capital away from the smaller innovative genomic science stocks. No meaningful news was published about the stock, though there were announcements that other care providers would be partnering with Invitae to add genetic testing to their service selection. Invitae is a relatively small and unprofitable company with massive growth aspirations.
Accelerating growth is giving investors more confidence in the genetic testing company's long-term prospects.